Biospective has leading expertise in models to evaluate the efficacy of novel therapeutic agents. We are a one-stop shop providing a full range of preclinical services, including in-house model generation, housing, dosing, imaging, behavioral testing, and histology/IHC studies.
Biospective has leading expertise in models to evaluate the efficacy of novel therapeutic agents. We are a one-stop shop providing a full range of preclinical services, including in-house model generation, housing, dosing, imaging, behavioral testing, and histology/IHC studies.
Biospective’s in vivo Parkinson’s disease mouse models rely on the inoculation of synthetic α-synuclein fibrils to initiate Parkinson’s disease-like Lewy bodies/Lewy neurites and transmit the pathology to anatomically-connected regions. These transgenic mice and α-synuclein fibril spreading PD models can mimic early “prodromal stage” or late “motor stage” of PD. Common injection sites include the striatum, the cerebral cortex, the substantia nigra, and the anterior olfactory nucleus (AON).
When synuclein is inoculated into the AON, the model shows neurodegeneration (which can be monitored longitudinally using in vivo MRI and neurofilament biochemistry), as well as progressive changes in olfaction and sleep. This alpha synuclein mouse model also shows neuronal loss and significant neuroinflammation by quantitative IHC.
Biospective’s in vivo Parkinson’s disease mouse models rely on the inoculation of synthetic α-synuclein fibrils to initiate Parkinson’s disease-like Lewy bodies/Lewy neurites and transmit the pathology to anatomically-connected regions. These transgenic mice and α-synuclein fibril spreading PD models can mimic early “prodromal stage” or late “motor stage” of PD. Common injection sites include the striatum, the cerebral cortex, the substantia nigra, and the anterior olfactory nucleus (AON).
When synuclein is inoculated into the AON, the model shows neurodegeneration (which can be monitored longitudinally using in vivo MRI and neurofilament biochemistry), as well as progressive changes in olfaction and sleep. This alpha synuclein mouse model also shows neuronal loss and significant neuroinflammation by quantitative IHC.
Biospective’s in vivo TDP-43 mouse model is useful for studying amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). This model demonstrates regulatable brain neurodegeneration, spinal motor neuron loss, and muscle denervation, resulting in a progressive, neurodegenerative phenotype. We have developed a robust set of biomarkers for this model, including in vivo MRI, in vivo FDG PET imaging, quantitative gait analysis, and quantitative IHC.
Biospective’s in vivo TDP-43 mouse model is useful for studying amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). This model demonstrates regulatable brain neurodegeneration, spinal motor neuron loss, and muscle denervation, resulting in a progressive, neurodegenerative phenotype. We have developed a robust set of biomarkers for this model, including in vivo MRI, in vivo FDG PET imaging, quantitative gait analysis, and quantitative IHC.
Biospective’s in vivo Tau transgenic mice and Tau fibril spreading models demonstrate a rapidly progressive and robust propagation of tau pathology. These models rely on the inoculation of synthetic tau fibrils to initiate Alzheimer’s disease-like intracellular neurofibrillary tangles and transmit the pathology to anatomically-connected brain regions. Common injection sites include the hippocampus, the cerebral cortex, and the anterior olfactory nucleus (AON).
Biospective’s in vivo Tau transgenic mice and Tau fibril spreading models demonstrate a rapidly progressive and robust propagation of tau pathology. These models rely on the inoculation of synthetic tau fibrils to initiate Alzheimer’s disease-like intracellular neurofibrillary tangles and transmit the pathology to anatomically-connected brain regions. Common injection sites include the hippocampus, the cerebral cortex, and the anterior olfactory nucleus (AON).
Biospective has both cuprizone and EAE multiple sclerosis mouse models. Biospective’s scientists work closely with sponsors to determine the most appropriate Cuprizone and EAE models, as well as biomarkers, to assess therapies targeting demyelination and remyelination, inflammation, and neuroprotection.
Biospective has both cuprizone and EAE multiple sclerosis mouse models. Biospective’s scientists work closely with sponsors to determine the most appropriate Cuprizone and EAE models, as well as biomarkers, to assess therapies targeting demyelination and remyelination, inflammation, and neuroprotection.
Biospective Inc.
Tel: +1-514-360-0141
Email: info@biospective.com
Address:
1255 Peel, Suite #560
Montréal (Québec), Canada H3B 2T9
©2022 Biospective Inc. | 1255 Peel, Suite #560, Montréal (Québec), Canada H3B 2T9 | info@biospective.com | 1-514-360-0141 | Privacy Notice | Sitemap